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Introduction: In immunocompromised patients, acute respiratory failure (ARF) is associated with high mortality,
particularly when invasive mechanical ventilation (IMV) is required. In patients with severe hypoxemia, high-flow
nasal oxygen (HFNO) therapy has been used as an alternative to delivery of oxygen via a Venturi mask. Our
objective in the present study was to compare HFNO and Venturi mask oxygen in immunocompromised patients
with ARF.
Methods: We conducted a multicenter, parallel-group randomized controlled trial in four intensive care units.
Inclusion criteria were hypoxemic ARF and immunosuppression, defined as at least one of the following: solid or
hematological malignancy, steroid or other immunosuppressant drug therapy, and HIV infection. Exclusion criteria
were hypercapnia, previous IMV, and immediate need for IMV or noninvasive ventilation (NIV). Patients were
randomized to 2 h of HFNO or Venturi mask oxygen.
Results: The primary endpoint was a need for IMV or NIV during the 2-h oxygen therapy period. Secondary
endpoints were comfort, dyspnea, and thirst, as assessed hourly using a 0–10 visual analogue scale. We randomized
100 consecutive patients, including 84 with malignancies, to HFNO (n = 52) or Venturi mask oxygen (n = 48). During
the 2-h study treatment period, 12 patients required IMV or NIV, and we found no significant difference between
the two groups (15 % with HFNO and 8 % with the Venturi mask, P = 0.36). None of the secondary endpoints
differed significantly between the two groups.
Conclusions: In immunocompromised patients with hypoxemic ARF, a 2-h trial with HFNO improved neither
mechanical ventilatory assistance nor patient comfort compared with oxygen delivered via a Venturi mask.
However, the study was underpowered because of the low event rate and the one-sided hypothesis.
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Acute respiratory failure (ARF) remains the most common
and severe life-threatening complication in immunocom-
promised patients [1–3]. Hypoxemic ARF can be related to
a variety of causes [4, 5], which must be identified by etio-
logical investigations conducted simultaneously with symp-
tomatic management. Many immunocompromised patients
with ARF require ventilatory support within a few hours
after admission to the intensive care unit (ICU) [6–8].
Avoiding invasive mechanical ventilation (IMV) signifi-
cantly decreases the risk of death [1, 3]. Thus, choosing the
optimal device for delivering oxygen is of the utmost
importance to decrease the IMV rate while maintaining
safe levels of oxygenation and ensuring patient comfort.
Noninvasive ventilation (NIV) has been reported to
decrease mortality in immunocompromised patients
with hypoxemic ARF [9]. However, NIV had smaller
benefits in the most recent studies, chiefly because of a
sharp drop in mortality among patients given IMV [10–13].
Moreover, NIV failure was associated with high mortality
[14, 15] and with patient discomfort and anxiety [16].
High-flow nasal oxygen (HFNO) therapy was first
introduced to treat children [17, 18], but it is now
increasingly used in adults managed in emergency
departments or ICUs [19–22]. This method consists of
delivering a high flow of humidified oxygen through a
large nasal cannula (HFNC). It not only delivers a high
fraction of inspired oxygen (FiO2) but also generates
some measure of positive pressure [23], ensures washout
of the nasopharyngeal dead space [23, 24], and diminishes
the work of breathing [25].
Few studies in adults have compared HFNO with oxy-
gen delivered through a facemask. Most of them were
small, uncontrolled, and used physiologic parameters as
the primary endpoints. They showed improvements in
oxygen saturation, partial pressure of arterial oxygen
(PaO2), patient comfort, respiratory rate, and dyspnea
[19, 21, 26, 27]. None compared intubation rates
between the two oxygen delivery methods. A retrospective,
uncontrolled study of 45 immunocompromised patients
treated with HFNO found a 66 % intubation rate [28].
In the present study, our objective was to compare
HFNO with oxygen delivered through a Venturi mask in
immunocompromised patients admitted to the ICU with
ARF. We conducted a multicenter randomized con-
trolled trial with the primary endpoint of need for NIV
or IMV within the first 2 h of oxygen therapy.
Methods
Overview
We performed an open, prospective, multicenter,
parallel-group randomized controlled trial in four ICUs
between November 2012 and April 2014. The appropri-
ate ethics committee approved the research protocol(Comité de protection des personnes Ile de France IX,
12 November 2011, RCB 2011-A00241-40). Informed
nonopposition consent was obtained from all patients
before study inclusion. The funding source (Fisher &
Paykel Healthcare, Auckland, NZ) provided the nasal
cannulas for HFNO and funds for insurance but had no
other role in the study.
Patients
Consecutive immunocompromised patients admitted to
the ICU for ARF were screened for inclusion. ARF was
defined as onset of respiratory symptoms within 72 h
before ICU admission and either a need for oxygen
greater than 6 L/min to maintain peripheral capillary
oxygen saturation (SpO2) above 95 % or symptoms of
respiratory distress (tachypnea >30/min, intercostal
recession, labored breathing, and/or dyspnea at rest). In
addition to ICU admission for ARF, inclusion criteria
were age over 18 years and immunosuppression (solid or
hematological malignancy, solid organ transplant, long-
term or high-dose [≥1 mg/kg/day] steroid therapy, other
immunosuppressive treatment, or HIV infection). Exclu-
sion criteria were hypercapnia (>45 mmHg), mechanical
ventilation before ICU admission, need for immediate
NIV or IMV, and patient refusal to participate in the
study. Patients who met all inclusion criteria and none
of the exclusion criteria were allocated at random in a
1:1 ratio, with stratification on study center, to HFNO or
oxygen delivery via a Venturi mask with the use of a per-
muted block method. Opaque, sealed envelopes ensured
identity concealment. The physician who included the
patient opened the sealed envelope and started the oxy-
gen device of the randomized group. The nature of the
study treatments precluded blinding.
Study treatments
Oxygen therapy was started immediately after inclusion.
In the Venturi mask group, FiO2 was 60 % (15 L/min)
initially and was then adjusted as needed to maintain
SpO2 of at least 95 %. Humidification was not applied.
In the HFNO group, HFNO was used with heated
humidified circuit, and initial flow was 40–50 L/min
with an FiO2 of 100 % and was then adjusted as needed
to maintain SpO2 of at least 95 %. Respiratory deterior-
ation in immunocompromised patients with ARF occurs
within the first few hours after ICU admission; we there-
fore confined the study to the first 2 h of HFNO or
Venturi mask oxygen delivery. No crossover between
the two treatments was allowed during this time window.
Data collection
The data were collected prospectively. The Simplified
Acute Physiology Score II (SAPS II) was computed
within 24 h of ICU admission, and the Sequential Organ
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sion [29, 30]. At randomization and after 60 and 120 mi-
nutes of study treatment, we recorded the respiratory
rate, heart rate, arterial blood pressure, SpO2, and FiO2.
At the same time points, the patients completed three
visual analogue scales (VASs; 0–10 scoring) on which 0
indicated absence and 10 the highest possible levels of
dyspnea, discomfort, and thirst, respectively. The cause
of ARF was established on the basis of predefined
criteria [6]. We recorded the need for NIV and/or
throughout the ICU stay and the ICU length of stay.
Endpoints
The primary endpoint was the need for IMV or NIV
during or at the end of the 2-h study period. IMV or
NIV was started in patients who met at least one of the
following criteria: worsening respiratory distress, defined
as SpO2 less than 92 %, respiratory rate more than 40
breaths/min or labored breathing, regardless of the oxy-
gen flow rate; inability to maintain PaO2 greater than
65 mmHg with FiO2 greater than 0.6; and hemodynamic
or neurologic deterioration. The choice between NIV
and IMV was at the physician’s discretion.
Secondary endpoints were the VAS scores for comfort,
thirst, and dyspnea; respiratory rate; and heart rate.
Statistical analysis
The sample size calculation was based on superiority of
the HFNC strategy. On the basis of an earlier study [31],
we expected oxygenation failure rates of 30 % in the
Venturi mask group and 10 % in the HFNC group at the
end of the 2-h trial. A sample size of 49 in each group
would have a power of 80 % to detect such a difference
(with a one-sided α of 0.05). The total number of
patients included was rounded up to 100.
All analyses regarding the primary outcome were per-
formed on the basis of the intention-to-treat principle.
We compared the proportion of patients with a primary
endpoint (including analyses of the separate components,
NIV or intubation and IMV) between the two strategies
and tested for significance using Fisher’s exact test.
Because the observed effect was in the opposite direction,
the tests were two-sided to ensure the possibility of asses-
sing the statistically significant superiority of the Venturi
mask strategy. Secondary continuous endpoints (comfort,
thirst, dyspnea, heart rate, and respiratory rate) were com-
pared between the two strategies among patients still
receiving the planned treatment at the end of the 2-h trial
using the Wilcoxon rank-sum test. All statistical analyses
were performed using R software (version 2.13.1).
Results
Figure 1 is the patient flowchart. Of 550 consecutive
immunocompromised patients admitted to the 4participating ICUs, 102 met our selection criteria and
were randomized: 53 to the HFNO group and 49 to the
Venturi mask group. In each group, one patient withdrew
consent. Thus, the final analysis included 100 patients: 52
in the HFNO group and 48 in the Venturi mask group.
Patient characteristics
We report the baseline patient characteristics in Table 1.
The most common causes of immunosuppression were
steroid or immunosuppressant treatment (n = 65) and
hematological malignancies (n = 61), and 15 % of pa-
tients had more than one cause of immunosuppression.
At ICU admission, the patients had tachypnea (respira-
tory rate, 27 [22–32] breaths/min) and SpO2 of 96 %
[94–98 %] under 12 [6–12] L/min of oxygen through a
standard oxygen mask, a SOFA score of 3 [2–5], and an
SAPS II of 39 [30–51]. The primary cause of ARF was
related to sepsis for 50 patients (Table 1).
None of the patients received oxygen through a Venturi
mask, HFNO, or NIV before randomization, which
occurred on day 0 [0–1] after ICU admission. Before
randomization, oxygen was provided through oxygen
prong, oxygen bagless mask, or oxygen bag mask. At base-
line, the VAS scores were 3 [2–5] for discomfort, 5 [2–7]
for dyspnea, and 6 [4–8] for thirst (Table 2 and Fig. 2).
Study endpoints
Of the 100 patients, 88 received the randomly allocated
oxygen treatment throughout the 2-h period and 12 re-
quired NIV or IMV before the end of the 2-h period.
There was no significant difference between the HFNO
and Venturi mask groups regarding the need for IMV/
NIV during the 2-h study period (Table 2).
None of the secondary endpoints differed significantly
between the Venturi mask and HFNO groups (Table 2
and Figs. 2 and 3). Moreover, we did not find an inter-
action between etiology of ARF (sepsis vs. no sepsis) and
efficacy of oxygen device (P = 0.44).
Subsequent outcomes
IMV was required within 1 day after randomization in
three additional patients: one in the HFNO group and
two in the Venturi mask group. Throughout their ICU
stay, a total of 39 patients required IMV. In patients
who required intubation after the end of the study
period, IMV occurred within 1 [0–2] day. Oxygen
was required for 5 [2–8] days. ICU length of stay was
7 [3–13] days, and ICU mortality was 24 %.
Discussion
In this randomized trial in immunocompromised
patients with ARF, mechanical ventilation requirements
within the first 2 h showed no significant difference
between HFNO and oxygen delivered via a Venturi
Fig. 1 Patient flowchart. HFNO high-flow nasal oxygen, ICU intensive care unit, IMV invasive mechanical ventilation, NIV noninvasive ventilation,
VAS visual analogue scale
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found for respiratory rate, dyspnea score, or heart rate.
Finally, patient comfort was not different between the
two treatments.
A randomized trial with a final crossover period com-
pared HFNO with standard nonhumidified oxygen
therapy in 37 consecutive ICU patients with ARF who
did not require immediate NIV or MIV [32]. Dryness
and discomfort were significantly lower in the HFNO
group. The patients were not immunocompromised, and
they had less severe hypoxemia compared with those in
our study. In a trial conducted in a cardiothoracic and
vascular ICU, researchers randomized 60 patients to
HFNO or heated and humidified oxygen therapy via a
standard facemask [31]. The need for IMV or NIV within
24 h was lower in the HFNO group (10.3 % vs. 30 %, P =
0.006). Neither comfort nor dyspnea was assessed. More-
over, most of the patients had undergone heart surgery
and were therefore likely to benefit from the positive ex-
piratory pressure delivered by HFNO [31]. Our patients
had severe hypoxemia and immune deficiencies. In arandomized trial with 310 patients with hypoxemic ARF,
the intubation rate was lower with HFNO than with NIV
or standard oxygen in the subgroup with the most severe
hypoxemia at baseline (PaO2/FiO2 ratio ≤200), but not in
the overall population [33]. In the FLORALI study, 26 %
of patients were immunocompromised. Among patients
with ARF, those with hematological malignancies more
often require NIV or IMV than other patients do [22, 31].
Thus, of 45 patients with hematological malignancies who
received HFNO for ARF, 30 (66 %) required IMV [28].
The failure of HFNO to decrease the need for
mechanical ventilatory assistance in our study may be
ascribable to several factors. The underlying disease
associated with immune deficiency (e.g., malignancy,
transplantation, or systemic inflammatory disease) may
have been a source of patient discomfort that was not
influenced by the mode of oxygen delivery. Second,
the time needed to improve oxygenation during ARF
may be longer in immunocompromised patients than
in other patients [34]. Thus, a longer trial would per-
haps have provided different results. However,
Table 1 Patient characteristics at randomization
Variables HFNO group Venturi mask group
(n = 52) (n = 48)
Age, yr, median [25th–75th percentile] 59.3 [43–70] 64.5 [53.25–72]
Males, n (%) 38 (73.1) 32 (66.7)
Comorbidities, n (%)
Chronic respiratory failure 7 (13.5) 4 (8.3)
Chronic kidney failure 2 (3.8) 3 (6.2)
Chronic heart failure 4 (7.7) 2 (4.2)
Cause of immunosuppression, n (%)
Solid malignancy 15 (28.8) 8 (16.7)
Hematological malignancy 31 (59.6) 30 (62.5)
HIV infection 3 (5.8) 5 (10.4)
Steroid treatment 13 (25.0) 15 (31.2)
Other immunosuppressant drugs 23 (44.2) 14 (29.2)
Final etiology of ARF,b n (%)
Sepsis 25 (48.1) 25 (52.0)
Cardiogenic pulmonary edema 5 (9.6) 2 (4.1)
Noninfectious pulmonary disease 5 (6.8) 7 (14.5)
Lung involvement by the underlying disease 7 (13.4) 9 (18.7)
Large pleural effusion 0 (0) 1 (2.0)
Pneumocystis pneumonia 5 (9.6) 2 (4.1)
Miscellaneousc 3 (5.7) 1 (2.0)
No diagnosis 2 (3.8 %) 1 (2.0)
SAPS II at ICU admission, median [25th–75th percentile] 42 [29.5–52] 37.5 [31.5–46.5]
SOFA score at randomization, median [25th–75th percentile] 3.5 [2–6] 3 [2–5]
Days since respiratory symptom onset 3 [2–8] 3 [2–7.25]
Clinical status at randomization
Respiratory rate, breaths/min, median [25th-75th percentile] 26 [21.7–31.2] 27 [22–32.2]
SpO2, %, median [25th-75th percentile] 96 [94–98] 96 [95–98.2]
Estimated PaO2/FiO2 ratio at admission 128 [48–178] 100 [40–156]
Mean arterial pressure, mmHg, median [25th-75th percentile] 86.8 [82.2–95.3] 80 [74–89.3]
Normal Glasgow Coma Scale score, n (%) 49 (94.2) 48 (100)
Confusion, n (%) 4 (7.7) 1 (2.1)
HFNO high-flow nasal oxygen, ARF acute respiratory failure, ICU intensive care unit, SAPS II Simplified Acute Physiology Score II (range 0–163 points, with worse
scores indicating greater disease severity), SOFA Sequential Organ Failure Assessment, SpO2 peripheral capillary oxygen saturation, PaO2/FiO2 ratio of partial
pressure of arterial oxygen to fraction of inspired oxygen
aThe groups were compared using the χ2 test for qualitative variables and the Wilcoxon test for quantitative variables.
bMore than one etiology could be suspected at admission.
cPulmonary embolism, lung metastasis, neutropenia recovery, extrapulmonary acute respiratory distress syndrome, drug-related pulmonary toxicity
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has been reported to occur chiefly within a few hours
of ARF onset [6]. Third, although researchers in most
studies of HFNO in adults used a 40 L/min oxygen
flow [19, 22, 23], as in our trial, there is some evi-
dence that higher flows may improve comfort by in-
creasing air humidification [25, 35]. Investigators in a
crossover study compared HFNO, oxygen via a Ven-
turi mask, and continuous positive airway pressure inten ICU patients immediately after tracheostomy re-
moval [23]. Each device was tested with three oxygen
flow rates (15, 30, and 45 L/min). However, in that
study as in our study, HFNO did not improve patient
comfort compared with the Venturi mask. Fourth, in
our 2-h study, NIV was not administered before
randomization. In a randomized trial of postextuba-
tion HFNO versus standard care in 340 heart surgery
patients, although the oxygenation failure rate was
Table 2 Primary and secondary endpoints in the two treatment groups
HFNO group Venturi mask group P value
(n = 52) (n = 48)
Primary endpoint
Number (%) of patients requiring mechanical ventilation 8 (15 %) 4 (8 %) 0.36
Noninvasive mechanical ventilation 6a 3a
Invasive mechanical ventilation 4 2
Secondary endpoints, median [25th–75th percentile]
Discomfort VAS scoreb at 120 min 3 [1–5] 3 [0–5] 0.88
Dyspnea VAS scoreb at 120 min 3 [2 – 6] 3 [1–6] 0.87
Thirst VAS scoreb at 120 min 6 [3–8] 6 [5 – 9] 0.40
Respiratory rate at 120 min, breaths/min 25 [22–29] 25 [21–31]
Heart rate at 120 min, beats/min 98 [90–110] 99 [83–112] 0.43
HFNO high-flow nasal oxygen, VAS visual analogue scale
aTwo patients in the HFNO group and one patient in the Venturi mask group received noninvasive ventilation followed by invasive mechanical ventilation
bAll three VASs ranged from 0 (absence of discomfort, dyspnea, or thirst) to 10 (worst possible discomfort, dyspnea, or thirst)
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with HFNO [36].
The present study has several limitations. We did not
use a crossover design. However, ARF can worsen
quickly in immunocompromised patients, confounding
the assessment of patient comfort, and we therefore lim-
ited the study period to 2 h [37]. HFNO patients
remained on HFNO throughout the 2-h study. Second,
sources of discomfort were not assessed. Discomfort canFig. 2 Changes in dyspnea, thirst and discomfort during the 2-h study per
assessed using 0–10 visual analogue scales on which 0 indicated absence o
dyspnea, thirst, or discomfort. The open bars represent the high-flow nasalbe due to dyspnea, HFNO-related noise, nasal obstruc-
tion, or sources unrelated to ARF or its treatment. In a
previous study, HFNO compared with a standard oxygen
mask did not significantly diminish nasal obstruction
but did improve comfort by decreasing dryness [32].
Moreover, in a recent study, airway dryness was different
in the two groups after 24 h. A longer study would allow
different results. A new HFNO device that is less noisy
has been developed but was not evaluated in our study.iod. Dyspnea (panel a), thirst (panel b) and discomfort (panel c) were
f dyspnea, thirst, or discomfort and 10 signified the worst possible
oxygen group and the gray bars the Venturi mask group
Fig. 3 Respiratory rate (panel a) and heart rate (panel b) changes during the 2-h study period. The open bars represent the high-flow nasal oxygen
group and the gray bars the Venturi mask group. Δ60-0 indicates the difference between randomization and the 1-h time point. Δ120-60 indicates
the difference between the 1-h and 2-h time points. Δ120-0 indicates the difference between randomization and the 2-h time point
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statistical assessment of factors independently associated
with IMV or NIV. Identifying such factors would be of
interest, as prolonged HFNO therapy might worsen out-
comes by delaying mechanical ventilation [37, 38].
Fourth, the statistical power of our study was lower than
planned, as the oxygen failure rate in the Venturi mask
group was 8 % instead of the expected 25 %. Moreover,
the study was initially designed to demonstrate superior-
ity of HFNC using a one-sided test; thus, it was clearly
underpowered to demonstrate the inferiority of HFNC
compared with the Venturi facial oxygen mask. At the
time the study protocol was developed, the number of
patients needed was assessed on the basis of Parke
et al.’s study, which was the only published study in
which intubation rate was compared between the two
devices. In the Parke et al. 's study, HFNO failure was
assessed within 24 h in cardiovascular patients. However,
ARF in immunocompromised patients could worsen fas-
ter and intubation could occur earlier than in cardiovas-
cular patients. For this reason, we did not perform a
crossover study. Within the short duration of our study,
we recorded a low failure rate. Patients intubated after
the study period required IMV within 1 [0–2] day. A
longer study period would produce different results.
Moreover, patients were admitted and included in the
study very early, without any other organ failure, but
they were severely hypoxemic and 39 % of them were ul-
timately intubated.
Conclusions
In immunocompromised patients with ARF, 2 h of
HFNO neither decreased the need for mechanical venti-
lation nor improved patient comfort. However, the studywas underpowered because of the low event rate and
one-sided hypothesis. Studies aimed at identifying the
sources of discomfort and targets for improvement are
needed, as are longer trials of HFNO in immunocom-
promised patients with ARF.Key messages
 In immunocompromised patients admitted to the
ICU with acute respiratory failure, the need for
noninvasive or invasive mechanical ventilation within
the first 2 h was not significantly different between
the group given high-flow nasal oxygen therapy and
the group given oxygen via a Venturi mask.
 No differences were found between the two groups
with regard to patient comfort, dyspnea, respiratory
rate, or heart rate.
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